Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The mean changes from baseline to Week 26 for fasting serum glucose were -32 mg/dL, -16 mg/dL and -27 mg/dL, and for body weight were -2.3 kg, -0.8 kg and +2.8 kg for BYDUREON, sitagliptin, and pioglitazone, respectively
This phase 3 global registration study involved 2,539 participants and met its primary endpoints for both mean percent change in body weight and the percentage of participants achieving 5% body weight reductions
Iron-Sulfur Cluster Biogenesis as a Critical Target in Cancer
A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 Administered as A Subcutaneous Bioresorbable 16mg Implant in Patients Undergoing Photodynamic Therapy (PDT) utilising Porfimer Sodium Results
US$ 29.85
US$ 24.82
US$ 25.40
